Zilovertamab vedotin not checked
Merck & Co. · MK-2140 · VLS-101
FollowEvery change as it happens, and a Monday email
Trials
8 active
11 in total · 8 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Intravenous (IV) Infusion 1.5 mg/kg, 1.75 mg/kg, 2.0 mg/kg, 2.25 mg/kg, 2.5 mg/kg”In the company’s words, NCT05139017 on ClinicalTrials.gov
- Tested for
- Diffuse Large B-Cell Lymphoma (4 trials), Lymphoma, Large B-Cell, Diffuse (2 trials), DLBCL, Lymphoma, Large B-Cell, Diffuse (DLBCL), Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma and 5 more
- Main trialPhase 3
- “The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.”In the company’s words, NCT06717347 on ClinicalTrials.gov
- Other names
- MK-2140 · VLS-101
Other drugs for Diffuse Large B-Cell Lymphoma
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- AcalabrutinibAstraZeneca · Phase 3
- EpcoritamabGenmab · Phase 3
- SHR-A1912Hengrui · Phase 3
- TisagenlecleucelNovartis · Phase 3
Coming up8
- 24 Sep 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 13 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 26 Feb 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 31 Mar 2029Phase 1/2 trial completes · ClinicalTrials.gov
- 26 Apr 2029Phase 2 trial completes · ClinicalTrials.gov
- 17 May 2029Phase 2 trial completes · ClinicalTrials.gov
- 2 Jul 2029Phase 3 trial completes · ClinicalTrials.gov
- 13 Mar 2037Phase 2/3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovStatus changed: Recruiting to Active, not recruiting · ClinicalTrials.gov NCT05562830
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 2 Jul 2029 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | |
| Phase 2/3Recruiting | 24 Sep 2027 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | |
| Phase 2/3Not yet recruiting | 13 Mar 2037 | A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | |
| Phase 2Recruiting | 13 Dec 2027 | A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | |
| Phase 2Active, not recruiting | 26 Apr 2029 | A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007) | |
| Phase 2Active, not recruiting | 17 May 2029 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | |
| Phase 1/2Active, not recruiting | 26 Feb 2029 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) | |
| Phase 1/2Recruiting | 31 Mar 2029 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | |
| Phase 2Terminated | 12 Jun 2023 | A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002) | |
| Phase 2Completed | 21 Apr 2026 | A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004) | |
| Phase 1Completed | 18 Dec 2023 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026